Business
Monument Therapeutics Success in Phase I Results
Monument Therapeutics Success in Phase I Results.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n\n\n \n24th June 2025\n \nCambridge Cognition Holdings plc\n(\"Cambridge Cognition\", the \"Company\" or the \"Group\")\nCambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment\nCambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved positive topline results from its Phase I clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia (CIAS).\nThe positive Phase I results, which demonstrated favourable safety and tolerability profiles for MT1988, represent an important milestone in addressing CIAS, which is a core aspect of schizophrenia that significantly impacts patients' daily functioning yet remains without approved treatment options. These results support the advancement of MT1988 into Phase II clinical development, targeting CIAS and related conditions.\nCambridge Cognition's proprietary digital cognitive assessment technologies were instrumental in the early development phases of understanding cognitive endpoints in this therapeutic area, contributing to the foundation upon which Monument Therapeutics has built its clinical programme.\nMonument Therapeutics was originally established by Cambridge Cognition as an independent precision neuroscience company to develop novel treatments for cognitive disorders, and the Group retains both an equity stake and a royalty structure in Monument Therapeutics that entitles it to future revenues arising from commercialisation of MT1988 and other programmes.\nRob Baker, Joint Managing Director and Chief Operating Officer, commented:\n\"We are delighted to see Monument Therapeutics achieve this significant milestone with MT1988. These promising results validate Monument's innovative approach to addressing the critical unmet need in CIAS and we remain hopeful that our investment, as well as potential future royalties, will be significantly value enhancing.\"\n \n \n \n \n \nEnquiries:\n \n\n\n\n\n\n\n\n\nCambridge Cognition Holdings plc \nRob Baker, Joint Managing Director and Chief Operating Officer\n \n\n\nTel: 012 2381 0700 \npress@...